Wednesday, 01 Apr 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels. https://t.co/meig18rSEX
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx http://t.co/wrucZOW9HC
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar https://t.co/IenWgRZUQL
22 Feb 2016 Social FDA has launch a CME course on biosimilars - reviews law, terminology, FDA approach to biosimilars https://t.co/5VDCzuiGNF
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar. https://t.co/EkikDMU1u8
11 Aug 2015 Social Tapering Biologic Tx Likely to Fail When ultrasound detected Synovitis Is Present http://t.co/j3nExzwW99
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA
22 Jul 2016 Social In Tofacitinib RCTs 1821 child-bearing age F exposed; 47 pregnant (33 monoRx). 1 Pulm valve stenosis, 7 Spont Abs. https://t.co/O2GT1BKiMT
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
05 May 2016 Social There is insufficient evidence that platelet rich plasma treatment benefits patellar tendinopathy. https://t.co/MIgQPx9kZR
29 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/OlN3Eyqya4
14 Jun 2018 Social RT @jomargwhite: MTX associated with reduction of CVD risk in patients reviving biologic treatment #eular2018 #methotrexate https://t.co/sl…
03 Oct 2018 Social RT @RheumNow: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheum…
19 Oct 2015 Social Here's a primer on Biosimilars, interchangibility and current issues under FDA review. https://t.co/UyhCBuQpsI
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb
13 Nov 2019 Social RT @EBRheum: Great talk by Dr. Manzi for Year in Review! See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NO…
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/iYAzWwsyi2